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ABSTRACT
Background: The approach to national and global
estimates of HIV/AIDS used by UNAIDS starts with
estimates of adult HIV prevalence prepared from
surveillance data using either the Estimation and
Projection Package (EPP) or the Workbook. Time trends of
prevalence are transferred to Spectrum to estimate the
consequences of the HIV/AIDS epidemic, including the
number of people living with HIV, new infections, AIDS
deaths, AIDS orphans, treatment needs and the impact of
treatment on survival.
Methods: The UNAIDS Reference Group on Estimates,
Modelling and Projections regularly reviews new data and
information needs and recommends updates to the
methodology and assumptions used in Spectrum. The
latest update to Spectrum was used in the 2007 round of
global estimates.
Results: Several new features have been added to
Spectrum in the past two years. The structure of the
population was reorganised to track populations by HIV
status and treatment status. Mortality estimates were
improved by the adoption of new approaches to
estimating non-AIDS mortality by single age, and the use
of new information on survival with HIV in non-treated
cohorts and on the survival of patients on antiretroviral
treatment (ART). A more detailed treatment of mother-to-
child transmission of HIV now provides more prophylaxis
and infant feeding options. New procedures were
implemented to estimate the uncertainty around each of
the key outputs.
Conclusions: The latest update to the Spectrum
program is intended to incorporate the latest research
findings and provide new outputs needed by national and
international planners.
Projections of adult HIV prevalence are prepared
using the Estimation and Projection Package (EPP)
1
for generalised epidemics and the Workbook for
low-level and concentrated epidemics.
2 The
Spectrum projection package is used to determine
the consequences of the prevalence projections,
including the number of people living with HIV by
age and sex, new infections, AIDS deaths, AIDS
orphans, the need for treatment and the impact of
treatment. Other demographic indicators of inter-
est, such as life expectancy and under-five mortal-
ity are also estimated. Earlier updates to Spectrum
have been described previously.
3 A full description
of the methodology is provided in the manual for
the AIDS module of Spectrum (AIM).
4 The
purpose of this paper is to describe the updates to
Spectrum made in the last two years and used in
the 2007 global estimates of HIV/AIDS.
Spectrum is a modular program that is used to
examine the consequences of current trends and
future programme interventions in reproductive
health. The program and manuals are updated
regularly and available in multiple languages free of
charge at www.FuturesInstitute.org. Model devel-
opment has been funded primarily by USAID with
technical collaboration from UNAIDS, WHO,
UNICEF, UN Population Division, US Census
Bureau, UNFPA and other organisations.
The major inputs and outputs of the AIDS
module of Spectrum are shown in figure 1.
Demographic projections are based on user inputs
or projections prepared by the United National
Population Division.
5 The projections start with an
estimate and projection of adult prevalence, which
is combined with information on the age and sex
distribution of prevalence and progression to death
to estimate the number of new adult infections by
age and sex. New infant infections are estimated
from prevalence among pregnant women and the
rate of mother-to-child transmission, which is
dependent on infant feeding practices and the
coverage of prophylaxis with antiretrovirals
(ARVs). New infections progress over time to a
symptomatic stage where antiretroviral treatment
(ART) is needed. Those who receive first-line and
or second-line ART experience extended survival.
People at any stage are subject to non-AIDS
mortality at the same rates as those who are not
infected. Adult deaths result in orphans.
Several major enhancements were made for the
2007 round of estimates in response to (1) a review
of the programme undertaken by the US Census
Bureau, (2) new evidence from cohort studies, (3)
revised child treatment guidelines, and (4) a need
to produce uncertainty bounds for all estimates.
The rest of this paper describes the changes to the
demographic procedures for projecting by single
age, a new pattern for the progression from new
infection to need for treatment and AIDS death,
new assumptions about survival on ART, revised
prevention of mother-to-child transmission
(PMTCT) treatment options and the new proce-
dures for estimating uncertainty.
NON-AIDS MORTALITY BY SINGLE YEAR OF AGE
Demographic projections rely on model life tables
to describe the age-specific pattern of mortality
corresponding to assumed levels of life expectancy
at birth. The standard tables, Coale-Demeny and
United Nations, show mortality in five-year age
bands that are suitable for demographic projections
made in five-year intervals. The rapidly changing
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Previously Spectrum produced single-year projections by divid-
ing the five-year mortality into equal amounts by single age. In
order to improve the estimates of non-AIDS survival ratios by
single years of age, the new Spectrum uses a modification of the
Beers
6 osculatory interpolation method to convert abridged
model life-tables into complete life-tables. The Beers method
has been used for many years by actuaries and demographers to
interpolate curves or populations based on five-year age groups
to single years of age.
7 The problem is that the rapid change in
the survival curve as a result of the relative level of infant-to-
child mortality makes it difficult for a generalised procedure to
reproduce that change. It has been observed that the Beers
estimate of the stationary population in a life-table (Lx) for age 1
is usually close to an independently derived value, but the
problem is the relative values of the age 0 (that is, under age 1)
and ages 2–4. In cases where an independent estimate of age 0 is
available (as in the case of model life-tables) the Beers estimate
for age 1 can be used and a polynomial can be fitted to the
independent age 0, the Beers age 1, residual 2–4, and Beers 5–8, 9
and 10. This results in a smooth curve of 1Lx that fits the
original 0, 1–4, and 5–9 and blends smoothly to the Beers
estimates for ages 10 and over. The resulting 1Lx values are then
used to estimate the survival ratios:
Sx=L x/Lx21 (1,=x,=79)
S0=L 0/l0
S80=T 80/T79
where Sx=one-year survival ratio from age x 2 1 to age x,
for x=0 from birth to age 0, for x=80 from age 79+ to
80+,L x=life-table stationary population age x, l0=radix of
life table, Tx=life-table stationary population ages x
and above.
PROGRESSION FROM INFECTION TO AIDS DEATHS IN THE
ABSENCE OF TREATMENT
Previous versions of Spectrum relied on estimates of survival
post-infection based primarily on one developing country study:
the natural history cohort of the MRC/UVRI study in Masaka,
Uganda
8 (with additional data from Haiti and a Thai military
cohort) implying a median survival time from infection to death
of 9 years. Recent analyses produced by the Alpha network
9
linking HIV cohort studies in a larger number of developing
countries widened the evidence base for estimating survival
patterns in HIV-infected adults.
10
Comparable analyses of data from studies in six different
countries
11–16 showed that survival times varied by study site
and age, with median survival times for those infected before
age 20 more than twice as high as for those infected aged 40
and over. A meta-analysis
17 showed that after adjusting to age
25–29 at seroconversion, median survival was longer in South
African miners, 11.6 years (95% CI 9.8 to 13.7) and African
population cohorts, 11.1 years (95% CI 8.7 to 14.2) than in
Haiti, 8.3 years (95% CI 3.2 to 21.4) and Thailand, 7.5 years
(95% CI 5.4 to 10.4). Median survival for women was about one
year longer than for men, but this was explained by their
younger age at infection. Before the introduction of ART, there
were no discernible trends in survival time by calendar year of
infection.
To make survival estimates for populations with different
levels of non-HIV mortality, ‘‘net’’ mortality patterns were
calculated in studies that also collected data on mortality
patterns of those not infected with HIV.
18 Net proportion
surviving x years after infection, SN(x), was calculated from
observed (gross) survival of infected people, SG(x), and the
corresponding survival for uninfected people, SU(x), using the
relation:
Figure 1 Inputs, outputs and process of the demographic and AIDS modules in Spectrum.
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grouped East African community studies (Rakai and Masaka in
Uganda, Kisesa in Tanzania), and for the South African miners
cohort, and shows a superimposed model representation of
‘‘net’’ mortality among HIV-infected people, generated by the
Weibull function with w=2 and l=13.21 (median 11 years):
In the Spectrum model representing survival post-infection
before the availability of ART, separate Weibull models are used
to represent male and female survival. For most countries the
male and female models have median survival times of 10.5
years and 11.5 years respectively, to allow for the older age at
infection for males compared to females. For Thailand,
Cambodia and Burma, the Thai cohort data are used to produce
Weibull models with median survival times of 8.1 years and 8.9
years respectively.
TIME TO ELIGIBILITY FOR ANTIRETROVIRAL TREATMENT
For a rising proportion of people living with HIV the progression
to AIDS death described above is modified by antiretroviral
therapy (ART). Previously eligibility for ART was estimated as
occurring two years before AIDS death. A number of cohort
studies provide new evidence on the time to eligibility. The
eligibility of antiretroviral treatment (ART) in lower income
countries (eART-linc) Collaboration is a collaboration between
five cohort studies of HIV-1-infected patients from Africa
19–22
and Thailand
23 24 initiated in 2007 by UNAIDS for collaborative
analyses of the natural history of untreated HIV infection in
lower-income countries. The eART-linc collaboration aimed at
estimating duration from seroconversion to different treatment
eligibility criteria, and duration from ART eligibility criteria to
death from all causes. By October 2007, the eART-linc
collaboration analysed 2072 seroconverters with 16 157 person-
years of follow-up from five cohorts from Co ˆte d’Ivoire,
19
Uganda
20–22 and Thailand.
23 24 Duration from seroconversion to
different ART treatment eligibility criteria was estimated by
fitting Weibull survival models, censoring individuals when
ART start was recorded or when last seen, whichever occurred
first. Consistency constraints were set so that the mean time
from seroconversion to death was equal to the sum of the mean
time from seroconversion to reaching ART eligibility and the
mean time from ART eligibility to death. The eART-linc
collaboration estimates for the median duration from ART
eligibility to death were from 2.1 years to 4.0 years for different
ART eligibility criteria.
The estimates of the time from ART eligibility to death (in
the absence of ART) were longer than those used in earlier
calculations of the number of people needing ART
25 and were
even longer when excluding the Thai studies from the analysis.
The main reason for this was that the models were built in a
way to incorporate the true—but never observed—time when a
person first reached ART eligibility. Despite the pooling of
several datasets in eART-linc, uncertainty of estimates was
substantial and the available data were too scarce to estimate
the relevant time periods in relation to the full ART eligibility
criteria as recommended by the World Health Organization:
patients who have either ,200 CD4 cells 610
6/l or WHO stage
4 disease or a combination of 200,CD4 cells 610
6/l ,350 and
WHO stage 3. Compared to the criterion of CD4 count below
200 cells 610
6/l, the combined WHO criteria would result in a
shorter time between seroconversion and reaching ART
eligibility, and a longer period between ART eligibility and
death in the absence of ART.
SURVIVAL ON ANTIRETROVIRAL THERAPY
In the past very little information was available on the
effectiveness of ART in averting death in developing countries,
but the recent expansion of ART has provided new data. A
literature review was conducted to update our knowledge about
survival after treatment initiation
26–35 (table 1). A systematic
review of published reports on survival among HIV-infected
patients on ART in LINCs has been conducted, focusing on
those reports investigating the factors associated with mortality
in adults and children. Three readers independently extracted
data from articles that were selected after screening of PubMed/
Medline up to December 2006 and abstracts of the 2001–6
international Conferences. Observational cohorts and clinical
trials and programme reports were eligible as long as they took
place in LINCs and included patients on ART. Only the studies
with the occurrence of death as outcome were included in this
review (the studies restricting their findings to the immunolo-
gical or virological response were excluded). The details recorded
included patient demographic characteristics, baseline CD4
count, survival estimate and factors associated with mortality
on ART.
For adult patients, a total of 25 articles were included in this
review among 878 screened. Twelve months after starting ART,
the overall mortality rate ranged from 0.06 to 0.26—that is, the
12-month probability of survival ranged from 0.74 to 0.94. It
was generally lower in patients starting ART with CD4 ,50
cells 610
6/l (range 0.67–0.91 610
6/l). The factors associated
with poorer survival among adults were low CD4 count (15
reports out of 15 studying this factor), advanced WHO stage 3
Figure 2 Net survival curves, for grouped studies from East Africa
(population cohorts), South Africa (miners occupational cohort) and the
fitted Weibull model.
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haemoglobinaemia, with different cut-off values (5/6 reports),
male gender (3/7 reports) and poor adherence (1/1 report). The
death rate was the highest in the first three months following
the initiation of ART (from 5.1 to 37.3 per 100 person-years
among five reports). For children, only three articles could be
included among 23 originally selected. The six-month survival
after ART initiation varied from 0.91 to 0.95. A low CD4
percentage was associated with poorer survival on ART. Little
or no data were available on survival according to the different
first-line regimens and the treatment switches occurring in the
first year on ART.
ART treatment programmes in LINCs have survival rates
comparable to those reported in developed countries in the early
phase of ART introduction 10 years ago.
26 The most recent
survival estimates of the ART-LINC Collaboration, pooling
individual adult data from 36 615 patients on ART in 17 cohorts
in Africa, Asia and South America, are 0.939 one year after
starting treatment (95% confidence interval: 0.936 to 0.942) and
0.929 after two years (0.926 to 0.932) (fig 3). However, the
frequency of patients lost to follow-up is of serious concern to
fully interpret the survival/mortality findings in the cohorts
reporting both events
36 (table 1). In the ART-LINC Cohort
Collaboration, the proportion of patients lost to follow-up in
the first six months on ART was as high as 16% among 7651
adults enrolled in 15 cohorts.
37 In Spectrum we have used values
of 0.85 for first-year adult survival on ART (rounded weighted
average from table 1). Data on survival in subsequent years are
sparse but are clearly much higher than first-year survival. We
have used 0.95 as the annual survival for subsequent years. The
annual survival for children over age 1 year on ART is set at 90%
in the first year of ART and 95% in subsequent years, based on
treatment results in children in Abidjan.
38 39 Survival on ART
among children under age 1 year is assumed to be 80%.
PROGRAMMES TO PREVENT MOTHER-TO-CHILD
TRANSMISSION OF HIV
Recent scientific and programmatic evidence has led to the
review of approaches to the use of ARV drugs in the context of
PMTCT. In general, longer prophylactic ARV regimens starting
earlier in pregnancy are more efficacious than shorter regimens.
Studies conducted in both Asia and sub-Saharan Africa have
shown that a combination regimen of AZT plus single-dose
nevirapine (SD-NVP) is more effective than single-drug regi-
mens in formula-fed as well as breastfeeding populations. AZT
plus SD-NVP is as effective as more complex regimens of AZT/
3TC starting at around 32-36 weeks given alone or plus SD-
NVP. In the absence of any intervention, postnatal transmission
of HIV accounts for 5% to 20% additional transmission rate.
Mixed feeding is associated with higher transmissions rates
compared with both replacement feeding and exclusive breast
feeding. Three major cohort studies conducted in Co ˆte d’Ivoire,
South Africa and Zimbabwe have shown that exclusive breast
feeding for up to six months is associated with a threefold to
fourfold decreased risk of postnatal transmission. While data
exist on the impact of single and dual prophylactic regimens on
postpartum transmission through breast feeding, the safety and
efficacy of ART on this mode of transmission is still under
investigation. However, programme data from Botswana, Cote
d’Ivoire, Mozambique and Uganda indicate that ART initiated
in pregnant women might reduce postnatal transmission
through breast feeding.
Table 1 Survival on ART, crude and adjusted for 100% mortality of patients lost to follow-up
Author, year Country of study
Sample
size
12-month
survival
Loss to
follow-up
Adjusted 12 months
survival assuming
100% of lost to
follow-up are dead
24-month
survival
36-month
survival
60-month
survival
Braitstein 2006
26 Africa, Asia, S America 2725 0.94 0.12 0.83
Calmy 2006
27 11 countries 6861 0.9 0.048 0.86
Etard 2006
28 Senegal 404 0.88 0.0195 0.86 0.83 0.75
Ferradini 2006
29 Malawi 1308 0.81 0.0385 0.78 0.72
Munderi 2006
30 Uganda 1015 0.94
Bourgeois 2005
31 Cameroon 109 0.92 0.028 0.89
Laurent 2005
32 Dakar 176 0.84 0.81
Lawn 2005
33 South Africa 578 0.93 0.071 0.86
Severe 2005
34 Haiti 910 0.82 0.078 0.76
Coetzee 2004
35 South Africa 287 0.86 0.007 0.85 0.86
Median survival 0.89 0.86 0.84
Weighted average 0.84
Standard deviation 0.05 0.08
Figure 3 Probability of death among 36 615 adult ART-treated patients
in 17 cohorts in Africa, Asia and South America (courtesy of ART-LINC
Collaboration).
Supplement
Sex Transm Infect 2008;84(Suppl I):i24–i30. doi:10.1136/sti.2008.029868 i27Concerns have been raised regarding the risk of decreased
virological response in women with viral resistance related to
intrapartum exposure to SD-NVP. Recent data showed that an
AZT/3TC ‘‘tail’’ given at the time of SD-NVP and for a short
time post partum reduces viral drug resistance when SD-NVP is
given either alone or in combination with AZT.
WHO recommends ART for all pregnant women who are
eligible for treatment. The goal is to secure the health of
women, significantly reduce HIV transmission to their infants
and improve child wellbeing and survival. For pregnant women
with HIV who do not yet require ART, antiretroviral
prophylactic regimens are recommended for the prevention of
MTCT. The recommended regimens are based around AZT
(from 28 weeks of pregnancy or as soon as possible thereafter)
plus single-dose nevirapine, plus maternal 7-day ‘‘tail’’ of AZT
and 3TC and one-week AZT for the infant.
Various ARV regimens for PMTCT are currently implemen-
ted in low-income and middle-income countries. These regi-
mens range from single drugs, such as SD-NVP and short-course
AZT, to dual and triple drugs. Spectrum has been updated to
include the full range of treatment and prophylactic options
now available and the distribution and duration of infant
feeding methods as shown in table 2.
UNCERTAINTY ANALYSIS
Spectrum produces a point estimate for each indicator for each
year. However, there may be a considerable amount of
uncertainty associated with each point estimate owing to: (1)
uncertainty around the prevalence curve produced by EPP or the
Workbook, and (2) uncertainty around input assumptions that
are based on studies from population samples in selected
countries. In previous rounds uncertainty bounds were esti-
mated by cumulating the uncertainty for each step in the
calculation for a typical generalised or concentrated epidemic
and applying the resulting bounds to all countries. In 2005 those
calculations were done for a large number of countries in each
category. For the 2007 estimates these procedures have been
added to Spectrum and are applied to estimate uncertainty
bounds for each country.
The prevalence trend is an input to Spectrum that comes
from EPP for generalised epidemics and from the Workbook for
low-level and concentrated epidemics as described in other
articles in this supplement. EPP generates 1000 prevalence
curves from its Bayesian melding approach and passes those to
Spectrum for use in this analysis. The Workbook method passes
just a series of annual estimates of adult prevalence. Spectrum
generates 1000 prevalence curves from the annual estimates of
prevalence by fitting a single logistic curve for countries where
prevalence is rising or stable and a double logistic curve if
prevalence is falling. The equation for the single logistic curve is:
Prevt=ae
a (t2t0)/(1+e
a (t2t0))
For the double logistic curve the equation is:
Prevt=a e
(t2t0)/(1+a e
(t2t0))6[2 a e
2b(t2t0)/(1+e
2b(t2y0))+b]
where a=parameter describing the asymptote, a=parameter
describing the rate of increase, t0=year the curve reaches one-
half of the asymptote, b=asymptote after the decline, b=rate
of decline.
For each of 1000 iterations the prevalence points are
randomly varied within some range and a logistic curve is fit
to the resulting points. The range of variation around each data
point is dependent on the quality of the surveillance used to
estimate prevalence. For countries with good surveillance
systems the range is 240% to +60% of the point estimate.
The range is increased to 248% and +102% for countries with
Table 2 Probability of mother-to-child transmission of HIV (%)
Duration of breast feeding in the
general population Treatment
Mixed breast
feeding
Replacement
feeding
Exclusive breast
feeding
Approximately 6 months None 26 20 23
Single-dose nevirapine 17 11 14
Dual-prevention ARV 10 4 7
Triple-treatment ARV 4 2 3
Approximately 12 months None 30.5
Single-dose nevirapine 21.5
Dual-prevention ARV 14.5
Triple-treatment ARV 5
Approximately 18 months None 35
Single-dose nevirapine 26
Dual-prevention ARV 19
Triple-treatment ARV 6
Mixed breast feeding: in addition to replacement feeding rates
First six months: 1% per month for first 6 months (total 6%) (based on reports by Iliff et al
45 and Rollins
46: approximately double the
hazard of exclusive breastfeeding).
Thereafter: 0.75% per month for next 6 months (total 4.5%) and for next 6 months (total 4.5%) (based on BHITS meta-analysis
47:
8.9% per 100 person-years).
Triple-treatment ARV: in absence of data, assume 2% additional transmission for first 6 months, then 1% for next 6 months and
again 1% for next 6 months.
Replacement feeding
No treatment: 20%: based on 2004 UNICEF/UNAIDS/WHO/UNFPA review.
40
Single-dose nevirapine: based on data from Jackson et al (11.8% at 6–8 weeks in breastfeeding population)
41 and Moodley et al
(10.7% among replacement feeding population).
42
Dual-prevention ARV: based on Ditrame (6.5% at 6 weeks (with some breastfeeding transmission))
43 and PPHT-2 (1.9–2.8% among
replacement feeding population).
44
Triple-treatment ARV: based on western studies quoted in report by UNICEF/UNAIDS/WHO/UNFPA.
40
Exclusive breast feeding
In addition to replacement breastfeeding rates: 0.5% additional transmission per month (total 3%) (based on reports by Iliff et al
45
and Rollins
46).
Triple-treatment ARV: in absence of data, assume 1% additional transmission.
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with poor quality surveillance systems. The quality of national
surveillance systems has been estimated on the basis of the
frequency and consistency of surveillance and the number of
urban and rural sites.
48
The Spectrum uncertainty analysis consists of a large number
of Monte Carlo runs, usually 1000, that each randomly select a
prevalence curve from the EPP or Workbook fits and input
values for other parameters from a range that can be set by the
user. The default ranges use standard deviations of 0.05 for
mother-to-child transmission rates, 0.2 for the effects of HIV on
fertility for 15–19 year old women, 0.1 for the effects of HIV on
fertility among 20–49 year old women, 0.10 for the effect of
cotrimoxazole on mortality and 0.05 for the ratio of female to
male prevalence. Ranges for the age distribution of prevalence
are estimated from national surveys of HIV prevalence in sub-
Saharan Africa. Ranges for the progression from infection to
need for treatment and need for treatment to death are
generated from Weibull curves that vary the median time of
progression by plus or minus two years. The user has the
opportunity to examine and change any of these default ranges
before processing. For example, the uncertainty around the
female-to-male prevalence ratio may be low in a country that
has recently had a national sero-survey but would be
considerably higher in a low-level or concentrated epidemic
without such a survey. Not all of these inputs will affect the
final results. For example, if cotrimoxazole is not used in a
particular country then variations in the assumption of
effectiveness of cotrimoxazole will not affect the estimate of
child AIDS deaths. Once processing starts Spectrum generates
1000 different runs randomly selecting values from these ranges.
The results are stored and then sorted to determine the ranges
for any percentile selected. We term these ranges plausibility
bounds to indicate that they are not true uncertainty ranges.
OTHER ENHANCEMENTS
There are a number of other updates to Spectrum for the 2007
estimates. All the demographic inputs have been updated to use
the 2006 round of estimates and projections from the United
National Population Division.
5 There are new utilities to ease
the manipulation of a large number of country files. These
utilities include Extract, which extracts the time series for any
indicator or selection of indicators from multiple Spectrum
projection files; Aggregate, which combines multiple projection
files into a single file for a region; and Scenario Generator, which
applies the same set of scenario projection assumptions for the
key HIV inputs across a selection of projection files.
Another new feature allows the input of incidence, rather
than prevalence, to drive the Spectrum projection. This is
particularly useful in examining the impact of prevention
interventions when the impact on incidence can be determined
or for examining the impact on prevalence of enhanced survival
due to ART.
STRENGTHS
The outputs of Spectrum include indicators useful for under-
standing the scope and magnitude of the epidemic, such as
numbers of people infected, new infections and AIDS deaths,
and indicators needed for planning the response, such as the
number of people needing treatment or PMTCT services. The
estimates are used by both national programmes and by
international agencies mobilising commitment and resources.
Recent updates to Spectrum incorporate the latest research
findings and allow national programmes to examine the
implications of those results for their programmes. Key
researchers contribute their expertise to the selection of
approaches and assumptions used in Spectrum through
participation in meetings of the UNAIDS Reference Group on
Estimates, Modelling and Projections.
LIMITATIONS
Many of the assumptions in Spectrum are derived from a small
number of studies. These studies may not be representative of
all populations. Many more studies are generally available for
African populations than for those in other regions. The results
from research studies with good service delivery and adherence
and may not reflect the impact that will be achieved when
implemented nationally. The new procedures to estimate
uncertainty rely on expert judgment and the variation found
within available studies and surveys. This may underestimate
the uncertainty caused by applying these assumptions to other
regions.
CONCLUSIONS
Spectrum is one of a package of tools that has been developed to
estimate the impact of the AIDS epidemic at the national level.
It continues to be updated to incorporate the latest research
findings and provide indicators needed for programme planning.
Recent updates of the progression from infection to death in the
absence of treatment have benefited from the experience of
long-running cohort studies and newer treatment cohorts have
provided valuable data on the effects of ART on survival. These
updates allow analysts from national programmes to estimate
their needs in order to achieve national goals for prevention and
treatment.
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